Neoadjuvant Immunotherapy: A Promising New Standard of Care
Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/14/11849 |
_version_ | 1797588934597804032 |
---|---|
author | Emma Boydell Jose L. Sandoval Olivier Michielin Michel Obeid Alfredo Addeo Alex Friedlaender |
author_facet | Emma Boydell Jose L. Sandoval Olivier Michielin Michel Obeid Alfredo Addeo Alex Friedlaender |
author_sort | Emma Boydell |
collection | DOAJ |
description | Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-small cell lung cancer on the basis of improvement in pathological response and event free survival. Nevertheless, current trials have only shown benefits in a fraction of patients. It is therefore crucial to identify predictive biomarkers to improve patient selection for such approaches. This review aims to provide an overview of potential biomarkers of neoadjuvant immunotherapy in early triple-negative breast cancer, bladder cancer, melanoma, non-small cell lung cancer, colorectal cancer and gastric cancer. By the extrapolation of the metastatic setting, we explore known predictive biomarkers, i.e., PD-L1, mismatch repair deficiency and tumour mutational burden, as well as potential early-disease-specific biomarkers. We also discuss the challenges of identifying reliable biomarkers and the need for standardized protocols and guidelines for their validation and clinical implementation. |
first_indexed | 2024-03-11T01:00:05Z |
format | Article |
id | doaj.art-d29eec4fdd634183a7cfdd02d750d5e6 |
institution | Directory Open Access Journal |
issn | 1661-6596 1422-0067 |
language | English |
last_indexed | 2024-03-11T01:00:05Z |
publishDate | 2023-07-01 |
publisher | MDPI AG |
record_format | Article |
series | International Journal of Molecular Sciences |
spelling | doaj.art-d29eec4fdd634183a7cfdd02d750d5e62023-11-18T19:46:01ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-07-0124141184910.3390/ijms241411849Neoadjuvant Immunotherapy: A Promising New Standard of CareEmma Boydell0Jose L. Sandoval1Olivier Michielin2Michel Obeid3Alfredo Addeo4Alex Friedlaender5University Hospital of Geneva, 1205 Geneva, SwitzerlandUniversity Hospital of Geneva, 1205 Geneva, SwitzerlandUniversity Hospital of Geneva, 1205 Geneva, SwitzerlandUniversity Hospital of Lausanne, 1005 Lausanne, SwitzerlandUniversity Hospital of Geneva, 1205 Geneva, SwitzerlandUniversity Hospital of Geneva, 1205 Geneva, SwitzerlandNeoadjuvant immunotherapy has emerged as a promising approach in the treatment of various malignancies, with preclinical studies showing improved immune responses in the preoperative setting. FDA-approved neoadjuvant-immunotherapy-based approaches include triple-negative breast cancer and early non-small cell lung cancer on the basis of improvement in pathological response and event free survival. Nevertheless, current trials have only shown benefits in a fraction of patients. It is therefore crucial to identify predictive biomarkers to improve patient selection for such approaches. This review aims to provide an overview of potential biomarkers of neoadjuvant immunotherapy in early triple-negative breast cancer, bladder cancer, melanoma, non-small cell lung cancer, colorectal cancer and gastric cancer. By the extrapolation of the metastatic setting, we explore known predictive biomarkers, i.e., PD-L1, mismatch repair deficiency and tumour mutational burden, as well as potential early-disease-specific biomarkers. We also discuss the challenges of identifying reliable biomarkers and the need for standardized protocols and guidelines for their validation and clinical implementation.https://www.mdpi.com/1422-0067/24/14/11849immunotherapyneoadjuvantpredictive biomarkersNSCLCmelanomaurothelial carcinoma |
spellingShingle | Emma Boydell Jose L. Sandoval Olivier Michielin Michel Obeid Alfredo Addeo Alex Friedlaender Neoadjuvant Immunotherapy: A Promising New Standard of Care International Journal of Molecular Sciences immunotherapy neoadjuvant predictive biomarkers NSCLC melanoma urothelial carcinoma |
title | Neoadjuvant Immunotherapy: A Promising New Standard of Care |
title_full | Neoadjuvant Immunotherapy: A Promising New Standard of Care |
title_fullStr | Neoadjuvant Immunotherapy: A Promising New Standard of Care |
title_full_unstemmed | Neoadjuvant Immunotherapy: A Promising New Standard of Care |
title_short | Neoadjuvant Immunotherapy: A Promising New Standard of Care |
title_sort | neoadjuvant immunotherapy a promising new standard of care |
topic | immunotherapy neoadjuvant predictive biomarkers NSCLC melanoma urothelial carcinoma |
url | https://www.mdpi.com/1422-0067/24/14/11849 |
work_keys_str_mv | AT emmaboydell neoadjuvantimmunotherapyapromisingnewstandardofcare AT joselsandoval neoadjuvantimmunotherapyapromisingnewstandardofcare AT oliviermichielin neoadjuvantimmunotherapyapromisingnewstandardofcare AT michelobeid neoadjuvantimmunotherapyapromisingnewstandardofcare AT alfredoaddeo neoadjuvantimmunotherapyapromisingnewstandardofcare AT alexfriedlaender neoadjuvantimmunotherapyapromisingnewstandardofcare |